Skip to main content

Table 1 Study outcomes

From: Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice

Index

Wild type group

Tpl2 knockout group

Animal number (n)

26

20

Final body weight (g)

41.2 ± 3.2

38.1 ± 5.9*

Liver weight (g)

2.5 ± 0.8

2.1 ± 0.3*

Liver/body weights (%)

6.2 ± 2.4

5.6 ± 1.1

Incidence of liver tumor (%)

100 % (26/26)

75 % (15/20)*

Liver tumor number/per animal

11 ± 6

10 ± 5

Histopathology of hepatic lesion#

n

%

n

%

Hyperplasia

26

100

3

15*

Hepatocellular adenoma

26

100

12

60*

Hepatocellular carcinoma

26

100

0

0*

Incidence of inflammation foci (%)

65.4% (17/26)

20 % (4/20)*

Inflammation foci number (cm2)

2.2 ± 2.4

0.6 ± 1.4*

Hepatic steatosis (median)

2

1*

Hepatic steatosis grading

n

%

n

%

 0

1

3.8

8

40

 1

2

7.7

4

20

 2

15

57.7

4

20

 3

8

30.8

4

20

  1. #Each animal has more than one type of lesions
  2. Values are expressed as means ± SD. An Independent t-test was performed except the comparison of incidence of liver tumor and inflammatory foci between WT and Tpl2 KO mice, which is conducted by nonparametric test. For steatosis, 20 images at 100 × magnification were captured for each section and blindly evaluated twice to determine grade of steatosis (both macro- and micro-vesicular) by two blinded investigators. The degree of steatosis was graded 0-3 based on the area of the liver section occupied by fat vacuoles. Data are presented as median (grading range) and Nonparametric test was used to test for statistical significance between groups for ordinal variable (liver steatosis score)
  3. For each given row, * indicates a significant difference between groups (P < 0.05)